Tens of millions of American adults take antidepressants, and many remain on the drugs for years without ever receiving a structured plan to stop. Depression — characterized by persistent sadness, low motivation, fatigue, sleep disruption, poor concentration, and loss of interest in daily life — affects nearly every system in your body when it becomes chronic. Left untreated, it increases your risk for metabolic dysfunction, social isolation, poor physical health, and even shortened lifespan.
Yet the conversation around treatment has started to shift dramatically. On May 4, 2026, the U.S. Department of Health and Human Services (HHS) announced a new national effort to address psychiatric overprescribing.1
This is important because many patients start antidepressants after brief appointments where lifestyle factors receive little attention. Sleep quality, movement patterns, sunlight exposure, and metabolic health rarely come up in those rushed visits, even though each one directly shapes how your brain regulates mood.
At the same time, serious questions continue to surround the research used to convince the public that antidepressants work exceptionally well long term. Investigators who reanalyzed one of the most influential federally funded depression trials reported that the original success claims were heavily inflated.2
When the data was reexamined using the study’s original rules, the picture of long-term recovery looked far bleaker than the version repeated in medical training and media coverage for nearly two decades. That growing disconnect between public messaging and real-world outcomes explains why federal agencies have started elevating exercise and other non-drug strategies as frontline mental health tools rather than backup options after medications fail.
Federal Agencies Push Back Against Psychiatric Overprescribing
In their announcement, HHS introduced a new action plan focused on reducing unnecessary psychiatric medication use, especially among children and adolescents.3 HHS Secretary Robert F. Kennedy Jr. said the initiative would “support patient autonomy, require informed consent and shared decision-making, and shift the standard of care toward prevention, transparency, and a more holistic approach to mental health.” The announcement framed psychiatric overuse as part of the broader mental health crisis facing the U.S.
• Federal agencies said they will review prescription patterns and medication risks — HHS stated that agencies are combining their expertise to evaluate how psychiatric medications are prescribed, their benefits, their harms, and the role of nonmedication approaches in mental health care.
The plan specifically mentioned “scalable, evidence-based solutions” and highlighted non-drug strategies such as psychotherapy, family support, nutrition, and physical activity. Officials also stated they want to prevent unnecessary psychiatric drug initiation and support tapering for patients who are not seeing meaningful clinical benefit.
• The initiative placed strong emphasis on informed consent and regular medication reviews — HHS released a “Dear Colleague” letter encouraging providers to prioritize shared decision-making and routinely discuss the risks and benefits of psychiatric medications with patients.
The guidance also encouraged clinicians to review whether medications are still helping over time instead of assuming long-term use automatically remains appropriate. The letter included information about billing codes that support evidence-based nonmedication treatments, making it easier for providers to offer alternatives beyond prescriptions.
• New guidance supporting deprescribing efforts — The Centers for Medicare & Medicaid Services (CMS) released guidance explaining how physicians and practitioners can receive Medicare payment for deprescribing-related care. Deprescribing refers to carefully tapering or discontinuing medications when appropriate rather than stopping suddenly.
CMS also directed clinicians to professional society guidelines, peer-reviewed deprescribing protocols, and U.S. Food and Drug Administration (FDA) taper instructions designed to reduce withdrawal problems and improve patient safety during medication reduction.
• HHS outlined multiple educational and policy initiatives scheduled throughout 2026 — The Substance Abuse and Mental Health Services Administration will release reports on prescribing trends and host educational webinars on psychiatric medication side effects, deprescribing approaches, and nonmedication treatments.
HHS also announced a July Technical Expert Panel involving health professionals, patients, government agencies, and professional societies to help develop formal guidance on psychiatric medication use and discontinuation.
• The federal plan also focused heavily on children and adolescents — HHS stated that agencies would support child-specific training for frontline prescribers and improve access to specialist consultations and evidence-based psychotherapy services.
CMS additionally announced plans to expand access to nonmedication care and reduce overreliance on psychiatric drugs for younger populations. At the same time, the National Institutes of Health and FDA said they are accelerating research into new mental health treatments as part of the broader federal initiative.
The Antidepressant Success Story Cracked
The federal push for greater transparency and informed consent didn’t happen in a vacuum, because growing scrutiny over the research behind antidepressant effectiveness had already started reshaping the conversation around psychiatric care. An investigative report published by Mad in America in 2023, written by Robert Whitaker, examined the STAR*D antidepressant trial, a federally funded study that shaped depression treatment guidelines for years.4
STAR*D originally claimed that nearly 70% of patients eventually became symptom-free after multiple medication attempts.5 Those results helped convince doctors, media outlets, and the public that antidepressants worked effectively for most people in real-world settings. The later analysis, however, argued that the reported numbers were inflated through protocol violations, selective reporting, and altered outcome measurements.
• The original study involved more than 4,000 patients treated with antidepressants in routine clinical settings — Researchers designed STAR*D to reflect what happens in ordinary medical practice rather than tightly controlled laboratory trials. Participants entered the study after struggling with persistent depressive symptoms severe enough to interfere with daily life.
Patients who failed one antidepressant were repeatedly switched to different drugs or combinations of drugs through four escalating treatment stages. That approach mirrored what many patients still experience today — trial after trial of different medications while searching for relief.
• Investigators later discovered the study changed its own rules during the process — According to the Mad in America analysis, the original STAR*D protocol measured remission using a structured interview conducted by trained clinicians — a rigorous, time-intensive assessment considered the gold standard at the time.
Partway through, researchers switched to a quick self-report questionnaire patients filled out themselves, and the looser tool produced noticeably rosier numbers, which dramatically improved the study’s public image.
• The difference between the reported success rate and the corrected success rate was enormous —The published reports promoted a cumulative remission rate of roughly 67%. Yet investigators who reanalyzed the data using the original study rules found remission rates closer to 35%. The corrected numbers showed that most participants failed to achieve lasting symptom relief despite repeated medication trials.
• Dropout rates and long-term recovery data painted a far different picture — Thousands of participants left the study before completion. Some stopped because of side effects. Others saw little improvement. Investigators also reported that only about 3% of the original 4,041 participants both improved and stayed well through the full study period. That “stay-well” number sharply contrasted with the optimistic public narrative repeated for years after STAR*D first appeared.
• If the corrected numbers are right, an entire generation of patients was misled — Researchers argued the study’s reporting influenced psychiatric care, physician training, and public trust in antidepressants for nearly two decades. Media organizations repeated the high remission numbers widely, reinforcing the belief that repeated medication switching reliably produced recovery.
Understanding how those numbers were constructed helps you ask better questions about long-term treatment strategies and why exercise, sleep restoration, metabolic health support, and psychotherapy now receive far greater attention as foundational mental health tools.
[…]
Via https://www.globalresearch.ca/kennedy-starts-push-help-americans-quit-antidepressants/5944052
